What Happened?
Shares of pharmaceutical company Organon (NYSE: OGN) fell 8.9% in the afternoon session after the company announced the resignation of CEO Kevin Ali after an internal investigation uncovered improper sales practices.
The audit found that certain U.S. wholesalers were asked to purchase more of the company's Nexplanon product than needed across multiple quarters in 2022, 2024, and 2025. According to the investigation, these actions enabled Organon to meet its financial guidance and revenue expectations. The board concluded the practices were improper and that some of the company's prior statements to investors were inaccurate or incomplete. Following the news, Organon's stock price plummeted as investor confidence was shaken. The company appointed Joseph Morrissey as Interim CEO to navigate the transition.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Organon? Access our full analysis report here.
What Is The Market Telling Us
Organon’s shares are quite volatile and have had 19 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 18 days ago when the stock dropped 3.2% on the news that worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.
Organon is down 56.9% since the beginning of the year, and at $6.45 per share, it is trading 65.7% below its 52-week high of $18.78 from October 2024. Investors who bought $1,000 worth of Organon’s shares at the IPO in May 2021 would now be looking at an investment worth $193.83.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
